Feds Say MDMA-Assisted Therapy for PTSD has Promise, but Needs More Research
Can psychedelics help veterans using MDMA-Assisted Therapy for PTSD? Federal officials think so, but they say thatcaution is key. So what else is new? Well, at least they continue to talk about it.
A recent gathering of federal officials sparked discussions on innovative PTSD treatments, including psychedelic assisted therapies. The meeting, while not exclusively focused on psychedelics, frequently touched on their potential.
The Reagan-Udall Foundation for the FDA organized this event. Representatives from various agencies, including the Department of Defense, HHS, FDA, SAMHSA, and VA, participated.
New: Interested in Being Part of a Psychedelics-Focused Clinical Trial? Sign Up Here
Why the buzz around psychedelics? Many attendees advocated for expanded access to MDMA and similar treatments. Betty Aldworth from MAPS noted the growing interest:
“Eighty members of Congress, the Veterans Affairs Administration, trauma experts, patient advocates, and 14 of 23 stakeholders who gave oral testimony agree the existing evidence base for psychedelic assisted therapies merit widespread, and growing, support.”
She urged action, stating, “It’s time to close the 25 year gap on new pharmacotherapies for the treatment of PTSD by approving this most promising treatment for PTSD and bringing psychedelic assisted therapies into the healthcare system.”
Read more on this story at Marijuana Moment.
MDMA-Assisted Therapy for PTSD – Balancing Promise and Caution
The FDA recently decided against approving MDMA assisted therapy for PTSD. This decision sparked mixed reactions. Leith J. States from the Office of the Assistant Secretary for Health addressed the issue:
“We all feel some type of way about the decision that came out some time ago, and that’s OK. It’s indicative of a fact that we’re moving forward and we’re stressing the system.”
Despite setbacks, States remained optimistic: “At the end of the day, we’re moving forward.”
Psychedelic AI is Here! Try out the beta version of HealingChat, HealingMaps AI chatbot that takes all our vetted content, clinics and retreats to answer all your questions in a safe environment. Try the beta version now!
Research Efforts Underway
The VA is taking steps to explore psychedelic therapies. Miriam J. Smyth, acting director of the agency’s Clinical Science, Research and Development Service, shared updates:
“We remind our veterans for their safety that they should not use psychedelics as part of a self treatment program.”
SAMHSA’s chief medical officer, Neeraj “Jim” Gandotra, echoed this cautious approach:
“Certainly we want to provide resources for evidence-based interventions that balance not only the therapeutic efficacy but also the risks that are associated.”
As research progresses, the focus remains on balancing potential benefits with patient safety. The journey to understand and potentially harness psychedelic therapies continues, guided by scientific rigor and cautious optimism.
